Marker Therapeutics Provides a Clinical Update on MT-601 in Patients with Lymphoma

APOLLO study investigating MT-601 in patients with relapsed lymphoma: 78% of patients achieved objective response rates, with 44.4% demonstrating complete response (CR)

Read more at globenewswire.com